Defined Financial Planning LLC Buys 26 Shares of Eli Lilly and Company (NYSE:LLY)

Defined Financial Planning LLC increased its stake in Eli Lilly and Company (NYSE:LLY) by 6.6% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 421 shares of the company’s stock after buying an additional 26 shares during the period. Defined Financial Planning LLC’s holdings in Eli Lilly and Company were worth $339,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also bought and sold shares of the stock. FMB Wealth Management bought a new stake in shares of Eli Lilly and Company during the first quarter valued at approximately $208,000. Yarger Wealth Strategies LLC increased its stake in shares of Eli Lilly and Company by 3.3% during the first quarter. Yarger Wealth Strategies LLC now owns 465 shares of the company’s stock valued at $384,000 after purchasing an additional 15 shares in the last quarter. Warner Financial Inc. boosted its position in shares of Eli Lilly and Company by 129.2% in the 1st quarter. Warner Financial Inc. now owns 1,123 shares of the company’s stock worth $927,000 after purchasing an additional 633 shares in the last quarter. Net Worth Advisory Group raised its stake in Eli Lilly and Company by 7.0% during the first quarter. Net Worth Advisory Group now owns 958 shares of the company’s stock valued at $792,000 after buying an additional 63 shares during the last quarter. Finally, Members Wealth LLC boosted its holdings in Eli Lilly and Company by 2.8% in the first quarter. Members Wealth LLC now owns 843 shares of the company’s stock worth $696,000 after acquiring an additional 23 shares in the last quarter. 82.53% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

LLY has been the subject of several recent analyst reports. Cantor Fitzgerald began coverage on Eli Lilly and Company in a research report on Tuesday, April 22nd. They issued an “overweight” rating and a $975.00 price target for the company. HSBC downgraded shares of Eli Lilly and Company from a “buy” rating to a “reduce” rating and reduced their price target for the company from $1,150.00 to $700.00 in a research report on Monday, April 28th. UBS Group decreased their price target on Eli Lilly and Company from $1,100.00 to $1,050.00 and set a “buy” rating for the company in a research note on Friday, May 2nd. Wall Street Zen raised Eli Lilly and Company from a “hold” rating to a “buy” rating in a report on Saturday, June 7th. Finally, Morgan Stanley reiterated an “overweight” rating on shares of Eli Lilly and Company in a report on Thursday, May 1st. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and eighteen have given a buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $1,011.37.

Eli Lilly and Company Stock Up 0.1%

NYSE LLY opened at $807.97 on Thursday. Eli Lilly and Company has a 12 month low of $677.09 and a 12 month high of $972.53. The company has a current ratio of 1.15, a quick ratio of 0.97 and a debt-to-equity ratio of 2.00. The stock has a market cap of $765.74 billion, a PE ratio of 69.00, a P/E/G ratio of 1.40 and a beta of 0.41. The stock’s 50 day moving average is $771.74 and its 200 day moving average is $800.91.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings data on Thursday, May 1st. The company reported $3.34 earnings per share for the quarter, missing analysts’ consensus estimates of $4.64 by ($1.30). The firm had revenue of $12.73 billion for the quarter, compared to analysts’ expectations of $12.77 billion. Eli Lilly and Company had a net margin of 23.51% and a return on equity of 85.24%. The company’s revenue for the quarter was up 45.2% on a year-over-year basis. During the same quarter in the previous year, the business earned $2.58 EPS. Research analysts predict that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Tuesday, June 10th. Stockholders of record on Friday, May 16th were issued a $1.50 dividend. The ex-dividend date of this dividend was Friday, May 16th. This represents a $6.00 dividend on an annualized basis and a dividend yield of 0.74%. Eli Lilly and Company’s dividend payout ratio (DPR) is presently 48.82%.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.